- Company
- General hospitals pass antifungal Cresemba for prescription
- by Eo, Yun-Ho Nov 18, 2020 06:35am
- South Korean general hospitals have started registering Pfizer’s novel antifungal Cresemba for prescription. According to pharmaceutical industry sources, the Drug Committee (DC) at the Big Five general hospitals and other healthcare institutes in South Korea, including Seoul Asan Medical Center and Severance Hospital, have cleared Cres
- Opinion
- [Reporter’s View] The sluggish shift in stepped pricing
- by Eo, Yun-Ho Nov 18, 2020 06:34am
- In June, South Korea’s Ministry of Health and Welfare (MOHW) issued an administrative notice to withdraw the plan to apply the stepped drug pricing reduction on drugs transferred by business restructuring. And it has been three months since the ministry completed collecting the public opinion in August. But the finalized notice has not been
- Company
- How can the domestic drug price system be improved?
- by Nov 17, 2020 06:28am
- As drugs that target specific genes or activate the immune system to treat diseases have been released, the use of one drug for various types of cancer has become more frequent. As of 2018, 75% of target anticancer drugs are multiple indications, and in the case of immune anticancer drugs, thousands of single and combined clinical trials for var
- Company
- A heated panel discussion on indication-basis drug pricing
- by Eo, Yun-Ho Nov 17, 2020 06:27am
- In this day and age of a single drug offering a variety of indications, the problem now lies on the drug pricing. The negotiation between the South Korean government and pharmaceutical company is slowing down and the patients have to wait longer as the country’s drug pricing system cuts the pricing when a drug expands its uses. On Nov.
- Company
- Korus Pharm is in charge of Russian COVID-19 vaccine
- by Kim, Jin-Gu Nov 17, 2020 06:27am
- It was confirmed that Korus Pharm, a small and medium-sized pharmaceutical company, is in charge of the Korean production of the Corona 19 vaccine developed by Russia. According to the pharmaceutical industry on the 13th, GL Rapha signed a three-party contract with the Russian Direct Investment Fund (RFID) and Yas Pharmaceuticals of the U
- Policy
- Multiple myeloma treatment 'Ninlaro' passed by the committee
- by Lee, Hye-Kyung Nov 17, 2020 06:27am
- Takeda Korea's multiple myeloma treatment'Ninlaro (Ixazomib)' passed the committee's deliberation. The HIRA (President Kim Sun-min) released the results of the deliberation on the adequacy of medical care benefits at the '11th Drug Benefit Evaluation Committee in 2020' on the 13th. The new drugs that have been deliberated on the adequac
- InterView
- “30-year-old Novarsc is our pride”
- by Eo, Yun-Ho Nov 17, 2020 06:26am
- Norvasc (amlodipine) is not the world’s first calcium channel blocker (CCB). However, it is undisputedly the most famous CCB. Launched in 1990s, Norvasc was not the first-in-class but it instigated a notable change in the market with the first once-daily administration. Some say the drug marked the early beginning of the present conven
- Policy
- Cyramza OS Clinical 9.6 months vs. RWE 7.9 months
- by Lee, Hye-Kyung Nov 17, 2020 06:26am
- Apparently a study in South Korea comparing the clinical trial result and real world data has found a targeted therapy for stomach cancer Cyramza (ramucirumab) and a targeted therapy for breast cancer Kadcyla (trastuzumab) have shorter overall survival in the real world. The clinical trial report on Cyramza stated its overall survival (OS) r
- Opinion
- [Reporter's View] Did they have to sell that day?
- by An, Kyung-Jin Nov 16, 2020 06:03am
- The whole world was excited when the news about COVID-19 vaccine developed by Pfizer last week was delivered. This is because Pfizer announced an interim result that the mRNA vaccine, which is being developed jointly with BioNTech in Germany, showed more than 90% prevention effect. The company recruited about 44,000 participants in clinic
- Policy
- No.1 anticancer drug in Rx sales is Palonosetron & Tamoxifen
- by Lee, Hye-Kyung Nov 16, 2020 06:03am
- Based on the number of prescriptions, gastric cancer patients were prescribed 'Palonosetron' and breast cancer patients were prescribed 'Tamoxifen' the most. The HIRA released a retrospective study on preparing a platform for real-world evidence (RWE) for drug reimbursement management (Research Director Dr. Dongsuk Kim, Dr. Jihye Byun). This
